Corvus Pharmaceuticals (CRVS) Long-Term Deferred Tax (2016 - 2022)
Corvus Pharmaceuticals (CRVS) posted quarterly Long-Term Deferred Tax of $54.9 million for Q4 2019, up 74.02% year-over-year from $31.5 million in Q4 2018, and up 74.02% quarter-over-quarter from $31.5 million in Q4 2018.
Corvus Pharmaceuticals (CRVS) Long-Term Deferred Tax (2016 - 2022) Analysis & Trends
Corvus Pharmaceuticals' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $54.9 million for Q4 2019.
- In Q4 2019, Long-Term Deferred Tax rose 74.02% year-over-year to $54.9 million; the TTM figure through Dec 2019 stood at $54.9 million (up 74.02% YoY), while the FY2019 annual figure was $54.9 million, up 74.02% from the prior year.
- Long-Term Deferred Tax for Q4 2019 stood at $54.9 million, up from $31.5 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $54.9 million in Q4 2019, with the low at $9.3 million in Q4 2016.
- The 4-year median for Long-Term Deferred Tax is $23.5 million (2017), against an average of $27.8 million.
- The sharpest annual moves came in 2017 and 2018: Long-Term Deferred Tax jumped 65.31% in 2017, then jumped 104.26% in 2018.
- Corvus Pharmaceuticals' Long-Term Deferred Tax stood at $9.3 million in 2016, then jumped by 65.31% to $15.4 million in 2017, then jumped by 104.26% to $31.5 million in 2018, then jumped by 74.02% to $54.9 million in 2019.
- Business Quant data shows CRVS's Long-Term Deferred Tax at $54.9 million in Q4 2019, $31.5 million in Q4 2018, and $15.4 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 76.95 Mn |
| Dec 31, 2021 | 68.02 Mn |
| Dec 31, 2020 | 56.14 Mn |
| Dec 31, 2019 | 54.87 Mn |
| Dec 31, 2018 | 31.53 Mn |
| Dec 31, 2017 | 15.44 Mn |
| Dec 31, 2016 | 9.34 Mn |